Drug Profile

Drug: Lixisenatide
Condition: Diabetes Mellitus Type 2
Brand Names: Lymunia
Keywords: GLP-1 mimetics, Glucagon-like peptide-1 receptor agonist, Blood Glucose lowering drugs, Type II
BNF Codes: Please select a BNF chapter code to go to the formulary.
060102 - Antidiabetic Drugs

Committee Recommendations

Date Committee Name Narrative Traffic Light Status Traffic Light Status
07 February 2018 Prescribing Clinical Network THE PREFERRED GLP-1 RECEPTOR AGONIST:
NICE advises selecting the GLP-1 receptor agonist based on the lowest acquisition cost, where all other factors are equal.

Treatment should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance
Green

Documents

Type: Document (click to view) Review Date
Guidelines (Local) Diabetes Type 2 -Treatment Guidelines - February 2018 Diabetes Type 2 -Treatment Guidelines - February 2018 PDF February 2021
Patient resource GLP-1 patient agreement form - February 2018 GLP-1 patient agreement form - February 2018 PDF February 2021
Information Antidiabetic treatments comparison- PrescQIPP resource - February 2018 Antidiabetic treatments comparison- PrescQIPP resource - February 2018 PDF February 2021
Information Hypoglycaemic agents -Preferred choices - February 2018 Hypoglycaemic agents -Preferred choices - February 2018 PDF February 2021
Information Blood glucose control - Treatment algorithm - February 2018 Blood glucose control - Treatment algorithm - February 2018 PDF February 2021

Supplementary documents (organisational specific)

No Supplementary Documents returned.